Drug firm Strides Pharma Science Wednesday reported a consolidated net loss of Rs 8.70 crore for the quarter ended September 30, 2018.
The company had posted a net profit of Rs 11.73 crore for the corresponding period of the previous fiscal, Strides Pharma Science said in a filing to BSE.
Consolidated revenue from operations stood at Rs 732.63 crore for the quarter under consideration. It was Rs 768.66 crore for the same period a year ago.
Commenting on the results, Strides Pharma Science Founder and Group CEO Arun Kumar said, "We have achieved significant progress on our reset strategy both in terms of course-correction and execution over the last two quarters."